Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd
Trade Name: Voceryq
Date Designated: 07/28/2020
Orphan Designation: Treatment of recurrent respiratory papillomatosis
Orphan Designation Status: Designated/Approved
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Suite 110
Plymouth Meeting, Pennsylvania 19462
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd
Trade Name: Voceryq
Marketing Approval Date: 10/30/2026
Approved Labeled Indication: to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis
Exclusivity End Date: TBD  
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-